|
Mar 25
|
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
|
|
Mar 22
|
Ionis Pharmaceuticals (IONS) Down 2.8% Since Last Earnings Report: Can It Rebound?
|
|
Mar 21
|
New Blood Thinners Will Prevent Blood Clots Without Causing Bleeding
|
|
Mar 17
|
30 Biggest Biotechnology Companies in the World
|
|
Mar 14
|
Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals
|
|
Mar 13
|
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
|
|
Mar 6
|
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
|
|
Feb 22
|
Q4 2023 Ionis Pharmaceuticals Inc Earnings Call
|
|
Feb 21
|
Ionis Pharmaceuticals Inc (IONS) Surpasses Revenue Guidance for 2023, Sets Sights on 2024 Growth
|
|
Feb 21
|
Ionis Pharmaceuticals (IONS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
Feb 21
|
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates
|
|
Feb 21
|
Ionis reports fourth quarter and full year 2023 financial results
|
|
Dec 30
|
EVP CLO & General Counsel Patrick O'Neil Sells 20,825 Shares of Ionis Pharmaceuticals Inc
|
|
Dec 24
|
Ionis Pharmaceuticals Inc EVP, Chief Scientific Officer C Bennett Sells 22,613 Shares
|
|
Dec 21
|
WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis
|
|
Dec 21
|
CORRECTED-UPDATE 2-US FDA approves Ionis-AstraZeneca's nerve disease drug
|
|
Dec 20
|
12 Most Promising Gene Editing Stocks According to Hedge Funds
|
|
Dec 20
|
Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 19
|
Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka
|
|
Dec 18
|
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema
|